• A previous comprehensive safety analysis of long-term adalimumab clinical data for the treatment of psoriasis from 13 clinical trials demonstrated a favourable safety profile for adalimumab in psoriasis.
What does this study add?
• Five additional adalimumab clinical trials in psoriasis have been completed since the November 2009 analysis.
• This comprehensive long-term integrated analysis of adalimumab safety in 3727 patients with psoriasis enrolled in 18 clinical studies found no new safety signals and was comparable with the previous safety report.
• The adverse event rates remained stable and consistent with currently approved labelled indications over increased adalimumab exposure time.
Long-term safety data are particularly important for therapies used over extended periods of time for the treatment of chronic conditions such as psoriasis, an immune-mediated inflammatory skin disease that affects 2-4% of the population in Western countries. 1 Extended exposure to immunosuppressants for the treatment of psoriasis could potentially lead to serious adverse events (AEs), including infections and malignancies. 2, 3 Adalimumab (Humira â , AbbVie Inc., North Chicago, IL, U.S.A.), a fully human monoclonal antibody specific for tumour necrosis factor (TNF)-a, is indicated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Additionally, adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis in the U.S.A.), Crohn disease, ulcerative colitis, hidradenitis suppurativa, uveitis, paediatric Crohn disease in the U.S.A. and Europe and severe chronic paediatric plaque psoriasis in Europe. Concerns have been raised about the long-term effects of TNF-a inhibitors such as adalimumab on the immune system and its ability to defend against serious infections such as tuberculosis (TB). 4 The long-term safety of adalimumab has been established in > 23 000 patients in clinical trials across multiple indications. 5 A previous comprehensive safety analysis of long-term adalimumab clinical data in psoriasis from 13 clinical trials (data cut-off 6 November 2009) that included 3010 patients with 4844Á7 patient-years (PYs) of exposure revealed no evidence of cumulative toxicity; 6 since then, five additional adalimumab clinical trials in psoriasis have been conducted. Here we provide an updated analysis of the safety of adalimumab in adult patients with moderate-to-severe plaque psoriasis using the most recent data cut-off (31 December 2015).
Patients and methods

Study design
This analysis included data from 18 clinical studies in adult patients with psoriasis (N = 3727), i.e. two phase II, doubleblind, placebo-controlled studies; one phase II/III, doubleblind, placebo-controlled study; five phase III studies; four extension studies; four phase IIIb studies and two phase IV studies (Table S1 ; see Supporting Information).
The main inclusion and exclusion criteria for most of the studies have been previously published. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Briefly, included patients were aged ≥ 18 years with a diagnosis of moderateto-severe psoriasis for ≥ 6 months. Patients who had received prior treatment with anti-TNF-a medications were excluded, except in extension studies, in which adalimumab could be continued, and in study W10-151, in which prior anti-TNF-a antagonists were permitted. Prior treatment with anti-TNF-a antagonists was not an exclusion criterion for study M10-238, but these treatments were discontinued before the administration of study medication. Detailed inclusion and exclusion criteria for all 18 clinical studies are listed in Table S2 (see  Supporting Information) . Adalimumab was administered subcutaneously in all treatment regimens. Dosing regimens are summarized in Table S1 (see Supporting Information) . The individual studies were conducted in accordance with the International Conference on Harmonisation guidelines, applicable regulations and the principles of the Declaration of Helsinki that were in place when the studies were conducted. The study protocols were approved by an independent ethics committee or institutional review board at each site and all patients provided written informed consent. The trials were registered at ClinicalTrials.gov (registry numbers NCT00645814, NCT00645905,  NCT00338754, NCT00237887, NCT00235820, NCT01646073,  NCT01644396, NCT02016482, NCT02533375, NCT00646191,  NCT02533375, NCT00645892, NCT00195676, NCT00647400,  NCT00566722, NCT00513370, NCT02196701, NCT00735787) .
The studies could be stopped if continued exposure to the study medication represented a significant risk to patients, as assessed by the sponsor or the investigator. Additional reasons for termination by the sponsor included safety concerns, unsatisfactory enrolment (quantity or quality), inaccurate or incomplete data collection, falsification of records and failure to adhere to the protocol.
Methodology for the integrated analysis
The analysis examined the All Adalimumab Treatment Set (AAT), defined as all patients from all studies in the adalimumab psoriasis clinical development programme who received at least one dose of adalimumab as part of any treatment regimen. Treatment-emergent AEs were collected from the first dose to 70 days after the last dose or the cut-off date (31 December 2015) and coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 18.1. AE reports were acquired automatically using lower-level group terms from the MedDRA; this differed from the methodology of the previous 2009 comprehensive safety analysis in which queries used MedDRA-defined preferred term group searches and company-defined preferred terms, requiring manual adjudication. AE incidence rates were expressed as events per 100 PYs (E/100 PYs) of exposure to adalimumab. Each patient was monitored by the investigator for clinical and laboratory evidence of AEs on a routine basis throughout the studies. AEs that were life-threatening, resulted in death, required hospitalization or prolonged a hospital stay, or resulted in a congenital anomaly or other medically important events were reported as serious AEs by the investigator or the sponsor. AEs commonly associated with adalimumab use (frequency 1-10%) were assessed and included nausea, fatigue, injection-site reactions including erythema, pain and pruritus, pyrexia, bronchitis, herpes zoster, influenza, nasopharyngitis, oral herpes, pneumonia, sinusitis, upper respiratory tract infection, urinary tract infection, antinuclear antibody positive, arthralgia, rheumatoid arthritis, headache, cough, pruritus and rash. Data from study M14-193 (generalized pustular psoriasis study; planned enrolment, n = 10; patients enrolled as of 31 December 2015, n = 5; patients receiving adalimumab as of 31 December 2015, n = 4) were excluded from most analyses, except for the standardized incidence ratios (SIRs) for malignancies and the standardized mortality ratios (SMRs).
The SIRs for malignancies were calculated as a ratio of observed to expected number of malignancies. The expected numbers of cancers, excluding nonmelanoma skin cancer (NMSC), were based on incidence rates from the National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) database from 2000 to 2007. 20 In situ cancers
were not included in the NCI SEER incidence rates; therefore, they were excluded from the SIR analysis. The NCI SEER database did not include NMSC; therefore, NMSC rates were taken from a 1977-1978 NCI survey carried out in the U.S.A., 21 which was the most recent available published data. The SMRs were calculated as the ratio of observed to expected deaths. Expected deaths were estimated based on PYs of treatment from the most recent World Health Organization (WHO) age-and country-specific mortality tables available at the time of analysis (1997-2006). 22 
Results
As of December 2015, 3727 patients with psoriasis received adalimumab and had a cumulative exposure of 5429Á7 PYs. Average exposure per patient was approximately 1Á5 PYs (17Á5 patient-months). Maximum duration of exposure to adalimumab was approximately 5Á5 years (> 288 weeks, n = 19; Fig. 1 ). Baseline demographics and clinical characteristics were similar between the 2009 and 2015 datasets ( Table 1 ). The mean age of patients was 44Á7 years, most patients were white, and the mean (SD) duration of psoriasis was 19Á0 AE 11Á7 and 18Á5 AE 11Á7 years at baseline in the 2009 and 2015 datasets, respectively. Patient disposition is summarized in Table S3 (see Supporting Information). 
Treatment-emergent adverse events
In the 3723 patients included in the safety analysis, there were 16 536 AEs, yielding an incidence of 304Á6 E/100 PYs; 3798 events (70Á0 E/100 PYs) were related to adalimumab as assessed by an investigator and 269 events (5Á0 E/100 PYs) led to discontinuation. Events leading to discontinuation included worsening of psoriasis (0Á3 E/100 PYs), prostate cancer (0Á1 E/100 PYs) and psoriatic arthropathy (0Á1 E/100 PYs); all other events leading to discontinuation had an incidence of < 0Á1 E/100 PYs. Incidence rates of the most frequently reported AEs (occurring in ≥ 5% of patients) were generally comparable with the 2009 dataset ( Table 2 ). The most frequently reported AEs were nasopharyngitis, upper respiratory tract infections and headache.
Treatment-emergent adverse events of interest
Overall, rates of serious AEs, serious infections and malignancies remained stable with increasing adalimumab exposure and were similar for the 2009 and 2015 datasets (Fig. 2a-c) . Increases in incidence rates for single 24-week periods were observed in both datasets for serious AEs (weeks > 192-216 owing to umbilical hernia, chest discomfort, humerus fracture, malignant melanoma, rectal adenocarcinoma, chronic kidney disease, urinary incontinence, nasal septum deviation, and in the 2015 dataset only, abdominal adhesions, osteoarthritis, procedural pain, pneumonia, postprocedural infection), serious infections (weeks > 216-240 owing to hepatitis C and osteomyelitis) and malignancies (weeks > 192-216 owing to malignant melanoma and rectal adenocarcinoma). There was an increase in malignancies in the 2015 AAT population compared with the 2009 AAT population during weeks > 240-264 [1Á9% (two events of basal cell carcinoma) vs. 0; Fig. 2c ].
At the cut-off date of 31 December 2015, serious AEs occurred at a rate of 8Á4 E/100 PYs and serious infections occurred at a rate of 1Á8 E/100 PYs ( Table 3 ). The most common serious infections were pneumonia (0Á3 E/100 PYs) and cellulitis (0Á2 E/100 PYs); all others occurred at a rate of ≤ 0Á1 E/100 PYs.
There were 43 malignancies excluding NMSC reported through 2015 (0Á8 E/100 PYs). A total of 10 events of melanoma were reported as of 31 December 2015, compared with nine events of melanoma in the 2009 dataset. Six patients with melanoma had a history of ultraviolet (UV)A (n = 1) or UVB (n = 3) treatment and/or significant sun exposure (one patient was a farmer with years of excessive sun exposure, one patient had significant sun exposure and developed cataracts and recent basal cell carcinoma, and one patient had a history of extensive sunbathing). One patient had a family history of metastatic melanoma. Five patients who developed melanoma had a duration of adalimumab treatment of < 6 months.
The incidence of malignancies excluding NMSC in patients treated with adalimumab for all body sites combined was comparable with the expected rate of diagnosed cancer for this demographic population, with an SIR of 0Á86 [95% confidence interval (CI) 0Á58-1Á23; Fig. 3 ]. There were 33 events of NMSC reported through 2015 (0Á6 E/100 PYs). In the 2009 analysis, 34 cases of NMSC were reported; the difference in the number of NMSC cases could be the result of the application of new search strategies to identify all potential reports. Specifically, one event with the preferred term of neoplasm skin and lower-level term of skin growth was included in the 2009 analysis but was not part of the NMSC search and did not meet the criteria for the 2015 analysis. The incidence of NMSC was elevated in patients treated with adalimumab, with an SIR of 1Á55 (95% CI 1Á10-2Á13; Fig. 3 ).
Nine fatal AEs and eight deaths (one death resulted from two fatal AEs) were reported in 2009. 6 One additional death from congestive heart failure occurred since then. An Asian male aged 38 years experienced congestive heart failure, severe myocarditis, pulmonary infection and arrhythmia. The patient had no known risk factors and this event was considered to be related to adalimumab treatment (adalimumab 40 mg every other week; exposure 114 days). The SMR was 0Á34 (95% CI 0Á16-0Á65) for the 2015 dataset; 0Á38 (95% CI 0Á16-0Á74) for men and 0Á19 (95% CI 0Á00-1Á06) for women. Based on these data, the patients exposed to adalimumab in psoriasis clinical trials had mortality rates no greater than the patients in the WHO database used for comparison. There were 16 reported events of TB (0Á3 E/100 PYs); nine were active (0Á2 E/100 PYs) and seven were latent (0Á1 E/ 100 PYs). Three patients had a positive purified protein derivative (PPD) test at screening. Since 2009, there were two new cases of active TB and seven new cases of latent TB. The two new cases of active TB were reported from the study in China, and four of the seven new cases of latent TB were reported from the study in Russia. Additionally, the rate of allergic reactions was higher for the 2015 dataset vs. the 2009 dataset (3Á9 vs. 1Á1 E/100 PYs). Rates of opportunistic infection were higher in the 2009 dataset; however, the 2015 analysis did not include oral candidiasis. Only one event (< 0Á1 E/100 PYs) of opportunistic infection (excluding TB and oral candidiasis) was reported in the 2015 dataset. A total of 11 events of oral candidiasis (0Á2 E/100 PYs) were reported in the 2015 dataset (Table 4) .
Lupus-like reaction and systemic lupus erythematosus incidence was 0Á04 E/100 PYs in the 2015 dataset (Table 3) ; cutaneous lupus was observed in two patients.
The most common AE of interest was injection-site reactions (11Á0 E/100 PYs). Other AEs of interest included depression (1Á5 E/100 PYs) and anxiety (1Á2 E/100 PYs); 31 of 74 patients with depression had previous history of depression and/or anxiety; one patient committed suicide (0Á02 E/100 PYs). Additional AEs of interest included herpes zoster [0Á8 E/ 100 PYs; seven of 458 events of herpes zoster in patients ≥ 60 years old (1Á0 E/100 PYs) vs. 37 of 3265 events in patients < 60 years old (0Á8 E/100 PYs)] and weight loss (0Á2 E/100 PYs; Table 4 23 and AE rates were consistent with other currently approved labelled indications for adalimumab over increased adalimumab exposure time.
The incidence rate of serious infection (1Á8 E/100 PYs) reported in this analysis was within the range of serious infection rates of 1Á0 E/100 PYs 23 and 1Á97 E/100 PYs 24 reported in patients with psoriasis receiving adalimumab in two realworld registries. The overall incidence rates of malignancies excluding NMSC remained stable from 2009 to 2015 (0Á7 and 0Á8 E/100 PYs, respectively). This is consistent with the rates of malignancies excluding NMSC reported for infliximab (0Á79 E/100 PYs) and other biologics (0Á49-0Á73 E/100 PYs) or nonbiologics (0Á46-0Á84 E/100PYs) reported by real-world registries. 25, 26 An increase in malignancies in the 2015 vs. 2009 AAT populations during weeks > 240-264 (1Á9% vs. 0) was due to two events of basal cell carcinoma.
While the SIRs for melanoma and NMSC were elevated in patients with psoriasis (SIR 3Á01, 95% CI 1Á11-6Á62 and SIR 1Á55, 95% CI 1Á10-2Á13, respectively) who participated in the adalimumab studies, the incidence rates remained stable from 2009 to 2015. There were nine events of melanoma (0Á2 E/ 100 PYs) in the 2009 dataset and 10 events (0Á2 E/100 PYs) in the 2015 set resulting from reclassification of lentigo maligna as a melanoma in the 2015 analysis. Half of these patients had adalimumab exposure for a duration that was likely too short (< 6 months) for a causal relationship. All 10 melanoma cases reported in this study had at least one confounding factor. Patients with psoriasis tend to seek natural UV exposure for its therapeutic benefits over the course of their lifetime more frequently than the average unaffected population. Of the 10 patients who developed melanoma, three had significant sun exposure. Other patients with melanoma had exposure to UVA or UVB. More frequent skin examinations by dermatologists in a clinical trial setting could lead to an increased chance of melanoma detection and could be an additional confounding factor when comparing the melanoma incidence with the NCI SEER general population rate. Melanoma cases could be potentially underreported in the NCI SEER database because data are primarily collected from hospital reports, thus raising the SIRs in this study. 27 Also, per NCI SEER, rates of new cases of melanoma of the skin have been rising on average 1Á4% each year over the last decade. As dermatologists have expertise in skin-related malignancies, NMSC diagnoses may be more likely in patients being treated for psoriasis, whereas SIRs may reflect comparison with general surveillance. Additionally, the elevated SIR for NMSCs may be attributable to the severity of the disease and/ or prior treatment. The risk of NMSC increased with increasing severity of psoriasis in a study of patients in the U.S.A. 28 Psoriasis treatment (including UVB, oral psoralen and UVA, and ciclosporin) has been associated with an increased risk of NMSC. 29, 30 However, it is unclear whether long-term treatment with TNF-a inhibitors directly increases the risk of cutaneous malignancies such as malignant melanoma or NMSCs; more definitive studies may be needed to provide a further evaluation of the effects of TNF-a inhibition on malignancies.
There were eight deaths in the 2009 analysis. We report one additional death from congestive heart failure that occurred since 2009. The mortality rate among patients exposed to adalimumab was no greater than the mortality rate among patients in the general population (SMR 0Á34, 95% CI 0Á16-0Á65). However, inclusion and exclusion criteria used in the clinical trials may affect the mortality rates, and the shorter durations of the clinical trials compared with the general population data may also affect the SMR. Although treatment with TNF-a antagonists has been associated with an increased risk of developing TB, 4 there are other risk factors as well, including age, country of origin or current residence, international travel, history of exposure to people with TB, disease activity and concomitant therapy with other immunomodulators. Two of the five new studies included in this analysis were conducted in China and Russia, where the incidence of TB is more than sixfold higher than in the U.S.A. and Canada. 31 Not unexpectedly, the majority of the new TB cases since 2009 were from the studies conducted in China and Russia; two new cases of active TB were reported from the study in China, and four of the seven new cases of latent TB were reported from the study in Russia. The other three new cases of latent TB (U.S.A. n = 2; Canada n = 1) may reflect newer protocols requiring annual TB exposure rescreens, which may have contributed to the increased rate. All patients receiving adalimumab were screened for TB using chest X-ray, PPD skin test, and/or interferon-c release assays. Isolated cases of PPD conversion were observed during adalimumab treatment.
There was an increase in the rate of allergic reactions from the 2009 analysis (1Á1 vs. 3Á9 E/100 PYs in 2009 vs. 2015, respectively). The higher incidence of allergic reaction in the 2015 analysis likely resulted from a change in search methodology for terms of interest from searches using preferred terms and manual adjudication to searches automatically acquiring lower-level group MedDRA terms. Of the 157 patients with allergic reactions in the 2015 dataset, 32 had a medical history of atopic diathesis, asthma, hay fever and/or atopic dermatitis in addition to other drug allergies.
The incidence of opportunistic infections reported in 2015 decreased from 2009 (0Á4 E/100 PYs in 2009 vs. 0Á02 E/100 PYs in 2015), which was likely due to the fact that the rates from the 2015 analysis excluded oral candidiasis but the 2009 analysis did not.
Limitations of the current analysis include the lack of a long-term comparator group. Comparisons were limited to population databases for SIRs (SEER database 2000-2007; NCI survey [1977] [1978] and SMRs (WHO mortality tables [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] . While patients with psoriasis may have received adalimumab in clinical practice for more than 10 years, the maximum duration of adalimumab treatment in the current analysis was 5Á5 years. Additionally, the clinical trial populations evaluated in this study may differ from the general clinical practice setting population because of the stringent inclusion/exclusion criteria inherent in clinical trials; hence, the interpretation of the data requires caution. As there is limited information regarding the long-term safety of biosimilar drugs, a safety comparison between originator adalimumab and biosimilars is currently not feasible.
Nonetheless, this comprehensive long-term integrated analysis of adalimumab safety in 3727 patients with psoriasis enrolled in 18 clinical studies found no new safety signals and was comparable with the previous safety report. The AE rates remained stable and consistent with currently approved labelled indications over increased adalimumab exposure time.
Data sharing
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinicaltrials/clinical-trials-data-and-information-sharing/data-and-info rmation-sharing-with-qualified-researchers.html.
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